Authors: Suzuki, Makoto; Iizasa, Toshihiko; Nakajima, Takahiro; Kubo, Rieko; Iyoda, Akira; Hiroshima, Kenzo; Nakatani, Yukio; Fujisawa, Takehiko

Source: Annals of Surgical Oncology, Volume 14, Number 9, September 2007 , pp. 2636-2642(7)

Publisher: Springer

Abstract:

Interleukin-12 receptor β2 (IL-12Rβ2) knock-out mice develop lung adenocarcinoma, and epigenetic silencing by CpG methylation leads to loss of this gene in B-cell malignancies. The aim of this study was to determine whether IL-12Rβ2 methylation is a common feature in human lung cancer.

We examined mRNA expression of IL-12Rβ2 in lung cancer cell lines, and normal bronchial, and tracheal epithelial cells using RT-PCR, and we examined the methylation status of IL-12Rβ2 in primary lung cancers.

Loss of expression was found in 10 of 13 (77%) NSCLC cell lines, and 2 of 5 (40%) SCLC cell lines compared with normal bronchial or tracheal cells. Treatment of 11 expression-negative cell lines with a demethylating agent restored expression in all cases. Aberrant methylation status of IL-12Rβ2 gene was reversely concordant with its mRNA expression. IL-12Rβ2 methylation was detected in 96 of 230 primary NSCLCs (42%) and 3 of 6 primary SCLCs (50%). IL-12Rβ2 methylation correlated with poorer prognosis in lung adenocarcinomas (hazard ratio = 2.33, P = 0.0059).

We conclude that epigenetic silencing of IL-12Rβ2 is a frequent event in lung cancers. Aberrant methylation of this gene seems to be a useful predictor of long-term outcome for adenocarcinoma of the lung.

Keywords: IL-12Rβ2; Methylation; Lung cancer; Prognosis

Document Type: Research article

DOI: http://dx.doi.org/10.1245/s10434-006-9310-7

Affiliations: 1: Email: fujisawat@faculty.chiba-u.jp

Publication date: 2007-09-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Oncology
• By this author: Suzuki, Makoto ;  Iizasa, Toshihiko ;  Nakajima, Takahiro ;  Kubo, Rieko ;  Iyoda, Akira ;  Hiroshima, Kenzo ;  Nakatani, Yukio ;  Fujisawa, Takehiko

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers